Literature DB >> 23964940

Inhibition of leukocyte trafficking in inflammatory bowel disease.

Fabio Cominelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23964940     DOI： 10.1056/NEJMe1307415

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

Review 1.  Review of vedolizumab for the treatment of ulcerative colitis.

Authors:  Michelle Sy Lau; Her Hsin Tsai
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 2.  Vedolizumab: first global approval.

Authors:  Raewyn M Poole
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

Review 3.  Integrin antagonists are effective and safe for Crohn's disease: a meta-analysis.

Authors:  Wen-Song Ge; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 4.  Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.

Authors:  Ersilia M DeFilippis; Randy Longman; Michael Harbus; Kyle Dannenberg; Ellen J Scherl
Journal:  Curr Gastroenterol Rep       Date:  2016-03

Review 5.  Mycobiota in gastrointestinal diseases.

Authors:  Pranab K Mukherjee; Boualem Sendid; Gautier Hoarau; Jean-Frédéric Colombel; Daniel Poulain; Mahmoud A Ghannoum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-11-11       Impact factor: 46.802

Review 6.  PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Man Cai Wang; Ling Yi Zhang; Wei Han; Yuan Shao; Mo Chen; Rui Ni; Gen Nian Wang; Feng Xian Wei; Ya Wu Zhang; Xiao Dong Xu; You Cheng Zhang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 7.  Targeting leukocyte trafficking for the treatment of inflammatory bowel disease.

Authors:  K O Arseneau; F Cominelli
Journal:  Clin Pharmacol Ther       Date:  2014-12-02       Impact factor: 6.875

Review 8.  Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives.

Authors:  Gian Eugenio Tontini; Maurizio Vecchi; Luca Pastorelli; Markus F Neurath; Helmut Neumann
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

9.  Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.

Authors:  Edward Shelton; Jessica R Allegretti; Betsy Stevens; Matthew Lucci; Hamed Khalili; Deanna D Nguyen; Jenny Sauk; Cosmas Giallourakis; John Garber; Matthew J Hamilton; Michal Tomczak; Fredrick Makrauer; Robert B Burakoff; Jonathan Levine; Punyaganie de Silva; Sonia Friedman; Ashwin Ananthakrishnan; Joshua R Korzenik; Vijay Yajnik
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

Review 10.  Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?

Authors:  Leah Gilroy; Patrick B Allen
Journal:  Clin Exp Gastroenterol       Date:  2014-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.